A University of Toronto-led study finds that of 1,357 FDA-cleared AI medical devices, only three have ever been tested on whether they improve patient outcomes like survival or hospitalization.
a2z Radiology AI's newly FDA-cleared tool flags seven acute conditions from a single abdomen-pelvis CT scan, and the startup says it cut radiologist reporting time by 17.8% in testing.
Leica Biosystems' newly FDA-cleared Aperio iQC DX caught up to 24% more slide defects than histotechnicians while cutting manual quality-review time by 69%, the company says.
A Nature paper from Nobel laureate David Baker's lab shows generative AI can design antibodies from scratch with atomic-level precision, bypassing the immune system entirely.
A retrospective Swedish study published in Radiology found that three commercial AI-CAD systems could have flagged subtle breast-cancer signs on mammograms years before radiologists caught them clinically.
The American Nurses Foundation and Hippocratic AI handed three nurse-led teams $10,000 microgrants to study AI's effect on patient safety and documentation — a grassroots counterweight to boardroom AI decisions.
Roche and Recursion Pharmaceuticals advanced the first validated target from their AI partnership on August 5, 2026 — a neurodegenerative disease target mined from a microglia data map of over a trillion cultured neurons, the first of up to 40 programs under their up-to-$12-billion deal.
A Nature Medicine study from Oxford, UCL, and the UK AI Security Institute ran 810 simulated conversations through nine AI chatbots and found mental-health risk builds gradually through 'Vulnerability-Amplifying Interaction Loops' rather than single bad replies.
Leica Biosystems announced FDA clearance on August 11, 2026 for Aperio iQC DX, the industry's first standalone AI quality control software for digital pathology, which detects up to 24% more slide-scan artifacts than manual review.
The FDA cleared Artera's ArteraAI Breast on May 6, 2026, the first digital pathology-based AI risk stratification tool for HR+/HER2-negative breast cancer, delivering same-day metastasis risk scores from existing biopsy slides.